Literature DB >> 23850902

Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension).

Shao-Liang Chen1, Feng-Fu Zhang2, Jing Xu2, Du-Jiang Xie2, Ling Zhou2, Thach Nguyen3, Gregg W Stone4.   

Abstract

OBJECTIVES: This study was designed to test the safety and efficacy of pulmonary artery (PA) denervation (PADN) for patients with idiopathic PA hypertension (IPAH) not responding optimally to medical therapy.
BACKGROUND: Baroreceptors and sympathetic nerve fibers are localized in or near the bifurcation area of the main PA. We previously demonstrated that PADN completely abolished the experimentally elevated PA pressure responses to occlusion of the left interlobar PA.
METHODS: Of a total of 21 patients with IPAH, 13 patients received the PADN procedure, and the other 8 patients who refused the PADN procedure were assigned to the control group. PADN was performed at the bifurcation of the main PA, and at the ostial right and left PA. Serial echocardiography, right heart catheterization, and a 6-min walk test (6MWT) were performed. The primary endpoints were the change of PA pressure (PAP), tricuspid excursion (Tei) index, and 6MWT at 3 months follow-up.
RESULTS: Compared with the control group, at 3 months follow-up, the patients who underwent the PADN procedure showed significant reduction of mean PAP (from 55 ± 5 mm Hg to 36 ± 5 mm Hg, p < 0.01), and significant improvement of the 6MWT (from 324 ± 21 m to 491 ± 38 m, p < 0.006) and of the Tei index (from 0.7 ± 0.04 to 0.50 ± 0.04, p < 0.001).
CONCLUSIONS: We report for the first time the effect of PADN on functional capacity and hemodynamics in patients with IPAH not responding optimally to medical therapy. Further randomized study is required to confirm the efficacy of PADN. (First-in-Man Pulmonary Artery Denervation for Treatment of Pulmonary Artery Hypertension [PADN-1] study; chiCTR-ONC-12002085).
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6-min walk test; 6MWT; CO; IPAH; MPA; N-terminal brain natriuretic peptide; NT-BNP; PA; PADN; PAH; PAOP; PAP; PVR; RA; RV; TPG; Tei; cardiac output; denervation; idiopathic pulmonary arterial hypertension; main pulmonary artery; pulmonary artery; pulmonary artery denervation; pulmonary artery hypertension; pulmonary artery occlusive pressure; pulmonary artery pressure; pulmonary vascular resistance; right atrium/atrial; right ventricle/ventricular; transpulmonary pressure gradient; tricuspid excursion index

Mesh:

Year:  2013        PMID: 23850902     DOI: 10.1016/j.jacc.2013.05.075

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  51 in total

Review 1.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

Review 2.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

3.  Key topics in pulmonary vascular diseases (assembly 13) from the European Respiratory Society 2018 Parisian Congress.

Authors:  Sheila Ramjug; Anton Vonk Noordegraaf; Marion Delcroix
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 4.  New trial designs and potential therapies for pulmonary artery hypertension.

Authors:  Mardi Gomberg-Maitland; Todd M Bull; Rajeev Saggar; Robyn J Barst; Amany Elgazayerly; Thomas R Fleming; Friedrich Grimminger; Maurizio Rainisio; Duncan J Stewart; Norman Stockbridge; Carlo Ventura; Ardeschir H Ghofrani; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 5.  Emerging therapies for right ventricular dysfunction and failure.

Authors:  Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

Review 6.  Pulmonary Artery Denervation: Update on Clinical Studies.

Authors:  Hang Zhang; Shao-Liang Chen
Journal:  Curr Cardiol Rep       Date:  2019-09-05       Impact factor: 2.931

7.  Nerve distribution of canine pulmonary arteries and potential clinical implications.

Authors:  Yun Zhang; Weijie Chen; Yanping Xu; Hang Liu; Yunlin Chen; Hanxuan Yang; Yuehui Yin
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 8.  Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2015-06-09       Impact factor: 29.690

9.  NPY/Y₁ receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension.

Authors:  S Crnkovic; B Egemnazarov; P Jain; U Seay; N Gattinger; L M Marsh; Z Bálint; G Kovacs; B Ghanim; W Klepetko; R T Schermuly; N Weissmann; A Olschewski; G Kwapiszewska
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

10.  2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Authors:  Chih-Hsin Hsu; Wan-Jing Ho; Wei-Chun Huang; Yu-Wei Chiu; Tsu-Shiu Hsu; Ping-Hung Kuo; Hsao-Hsun Hsu; Jia-Kan Chang; Chin-Chang Cheng; Chao-Lun Lai; Kae-Woei Liang; Shoa-Lin Lin; Hsao-Hsun Sung; Wei-Chuan Tsai; Ken-Pen Weng; Kai-Sheng Hsieh; Wei-Hsian Yin; Shing-Jong Lin; Kuo-Yang Wang
Journal:  Acta Cardiol Sin       Date:  2014-09       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.